Parth Mehrotra, Chief Executive Officer of Privia Health Group (NASDAQ: PRVA), executed a sale of 21,097 shares of common stock on March 10, 2026, totaling approximately $479,112. The trades were carried out at prices between $22.27 and $23.23, according to a Form 4 filing with the Securities and Exchange Commission.
The Form 4 indicates the disposition was made pursuant to a pre-established Rule 10b5-1 trading plan. At the time of the transactions the stock was trading at $21.73 and had declined by about 9% over the previous week, per InvestingPro data cited in the filing.
The same filing shows that Mehrotra also received equity awards in the same period: 141,342 shares were granted on March 10 and 171,904 shares on March 11. Those grants were issued as restricted stock units (RSUs) and performance stock units (PSUs) under the company’s 2021 Omnibus Incentive Plan, as recorded in the filing.
InvestingPro analysis included in the filing commentary characterized the stock as appearing undervalued at current market levels and assigned Privia a Financial Health Score of 3.03 out of 5, labeled as "GREAT."
Separately, Privia Health reported financial results for the fourth quarter of 2025 that exceeded consensus forecasts. The company posted earnings per share of $0.99, well above the $0.04 analysts had forecast. Revenue for the quarter totaled $541.17 million versus an expected $515.86 million.
Those results prompted positive responses from sell-side analysts. Jefferies raised its price target on Privia Health to $32 while maintaining a Buy rating. Piper Sandler increased its price target to $36, citing the company’s strong fourth-quarter performance and constructive guidance for 2026.
According to the reporting that accompanied the analyst commentary, Privia’s performance outpaced consensus across several operating metrics, including Implemented Providers, Revenue, Care Margin, and Adjusted EBITDA. Both Jefferies and Piper Sandler maintained favorable outlooks following the earnings release.
This combination of insider activity - a scheduled sale under a 10b5-1 plan alongside substantial equity awards - and the company’s materially stronger-than-expected quarterly results creates a mixed set of disclosures for investors to weigh. The filings and analyst reactions together document recent management compensation events and independent analyst reassessments in response to reported results.